Document is current
Any future updates will be listed below
-
Authors
Luo, Hanzhi https://orcid.org/0000-0002-4906-967X
Kharas, Michael G. https://orcid.org/0000-0002-1165-6991
Jaffrey, Samie R. https://orcid.org/0000-0003-3615-6958
- License Information
-
More Information
Article History
Accepted: 17 October 2025
First Online: 8 December 2025
Competing interest
: H.L. has no competing interests. M.G.K. is a SAB member of 858 Therapeutics and received laboratory support from AstraZeneca, plus consulting and laboratory support from Transition Bio. S.R.J. is the co-founder, adviser and/or has equity in Chimerna Therapeutics, 858 Therapeutics and Lucerna Technologies.
